Achieved over the last months

Anticipated in the next 12 months

COVA

  • Positive results of phase 2-3 COVA study
  • Launch of Early Access programs in France and Brazil
  • Application for conditional marketing authorisation in Europe and in the US

SARA

  • Autorisation to start phase 3 SARA-31 study in Belgium and the US
  • Start of phase 3 SARA-31 study depending on financial resources and partnership

MYODA

  • Preparation of an amended protocol to regulatory agencies (FDA, EMA)
  • Submission of an amended protocol to regulatory agencies (FDA, EMA)
  • Start of phases 1/2 study